Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep Tang is just about done. 2.3 million shares total left that's it no other preffered shares
Press release is out for First quarter financial results plus a business update
http://finance.yahoo.com/news/rxi-pharmaceuticals-reports-first-quarter-110500300.html
What I find impressive is that Opko owns 7.2%. I have a gut feeling that Opkos has future plans to up the stake in RXII or eventually buy it out.
Both Posters up for Tyrosinase and Collagenase on Rxi website under company presentations
http://investors.rxipharma.com/Cache/1500071778.PDF?Y=&O=PDF&D=&fid=1500071778&T=&iid=4418218
http://investors.rxipharma.com/Cache/1500071779.PDF?Y=&O=PDF&D=&fid=1500071779&T=&iid=4418218
Retinoblastoma poster results are out. Read it from website:
Basically reduced protein levels and reduced oncogene levels of the MYCN oncogene. Good news
http://investors.rxipharma.com/Cache/1500071642.PDF?Y=&O=PDF&D=&fid=1500071642&T=&iid=4418218
Totally agree and have you guys seen the data from the Retinoblastoma description from ARVO meeting?
sd-rxRNA not only suppresses the Retinoblastoma tumor but also shrinks it.
http://www.arvo.org/webs/am2015/abstract/509.pdf
page 14 of the abstracts.
New RXII Presentation is up on the website now for viewing looks good
http://investors.rxipharma.com/Cache/1500071375.PDF?Y=&O=PDF&D=&fid=1500071375&T=&iid=4418218
I stated many times when a company files an IND it only takes 3 to 6 months max to get the phase 1 trial approved for clinical use.
The fact that its already 2 years in and BMSN is still struggling with safety of the IND should be huge red flags for investors to stay away.
Tang capital had 6 million shares as of 5/30/15 probably so if he had been selling through all of April he is probably down to $1 million shares left which means he is almost irrelevant in the long term of things.
Hopes you like my RXII article ? Here it is: http://seekingalpha.com/article/3121906-rxi-pharmaceuticals-one-undervalued-biotech-that-keeps-building-its-pipeline-for-future-value
yes I'm hoping Tang is out completely. Quite honestly Tang is toxic and I will never invest again in a stock that has tang capital a part of it.
If not for Tang Capital RXII would be trading roughly $7 to $10 per share by now after all the good news events we got.
With respect to scarring market will react more when we get additional data by the end of 2015 but I think two things will move the share price up.
IND for macular degeneration scarring in mid 2015 is one of them and the second would be poster data from Retinoblastoma this coming Thursday May 7.
Retinoblastoma will get praise from investors and doctors alike because it is a cancerous eye tumor in children under the age of 5 with limited treatment options. Good pre-clinical data may be enough to get the share price moving big.
Did you also see the poster data on Retinoblastoma coming up next thursday? I didn't even know Retinoblastoma was still in the pipeline but seeing data will be good.
RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences
http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-upcoming-presentations-110200384.html
I see that Tang has converted a lot of preffered shares and continues to convert. Many thought he would stop converting so it got me thinking.
Why would a preferred shareholder convert all their preferred shares continuously even though nothing but good news is coming out? So I did a little digging and found this excerpt Rxi's 10-k SEC filing which is on page 26.
"The holders of our Series A and Series A-1 convertible preferred stock may be able to delay or prevent a change in corporate control that would be beneficial to our stockholders."
The above quote is in bold in the SEC filing on page 26 while nothing else is in bold letters other than this excerpt
"Provisions of our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change of control of the Company or changes in our management and, as a result, depress the trading price of our common stock."
So it has me thinking what company would want to buy or merge with Rxi Pharmaceuticals? One possible merger or acquirer in my opinion would be Opko health with Dr. Frost. Dr. Frost already owns 7% RXII. Maybe he wants to acquire or merge the company with his. It could possibly be another bid or hostile takeover. All this is a theory but it makes sense considering the preferred shareholder is selling out completely despite positive news.
Good for you! Koos is just stringing investors along to collect a paycheck. Have you seen his suits, watches etc. Investors are all paying for that while Koos produces nothing of value.
Koos has been talking about an IND on Xemahallerate since 2011. It doesn't take that many years for an IND ............
RXi Pharmaceuticals Receives Orphan Drug Designation for Samcyprone™ from the U.S. FDA for the Treatment of Malignant Melanoma Stage IIb to IV
http://finance.yahoo.com/news/rxi-pharmaceuticals-receives-orphan-drug-115000347.html
Schedule 14a SEC fling filed for June 1, 2015 meeting. Check out item #3
http://investors.rxipharma.com/Cache/c28999994.html
At the Annual Meeting, you will be asked to consider and vote upon: (1) the election of the five director nominees named in the accompanying proxy statement; (2) the ratification of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015; and (3) the transaction of any other business that may properly come before the meeting or any adjournment thereof. Pursuant to the Company’s bylaws, no other items of business are expected to be considered at the meeting and no other director nominees will be entertained.
See how item #3 is snuck in there. Something is going down with RXII I don't know what but something good I'm assuming
RXI Pharma (RXII) receives FDA orphan status for samcyprone
April 16, 2015 8:04 AM EDT
http://www.streetinsider.com/FDA/RXI+Pharma+%28RXII%29+receives+FDA+orphan+status+for+samcyprone/10463504.html
The $20 million dollars in dilution and warrants sounds bad but read all the way through. Well I won't make you read it all but check out page 62 of the S-1 filing under "plan of distribution"
Then read this quote here:
"We will enter into securities purchase agreements directly with certain institutional investors which will purchase not less than $ of securities in this offering. We will not enter into any securities purchase agreement with investors which will purchase less than $ of securities in this offering and such investors which purchase less than $ shall rely solely on this prospectus in connection with the purchase of securities in this offering. The Placement Agent may retain one or more sub-agents or selected dealers in connection with the offering."
RXII is actually selling directly the shares to institutional investors. That's a good thing!
The collaborations with MirImmune ( I guess some people question this one since its with Alexey Wolfson as CSO) and PCI Biotech are good collaborations. Both these companies want to use the sd-rxRNA platform to deliver siRNA molecules to protein targets.
1.MirIMMUNe wants to target cancer proteins with immunotherapy checkpoint inhibitors
2.PCI biotech wants to use siRNA molecules against cancer cells combining their gene together with the sd-rxRNA delivery platform.
Hypertrophic scar study 1301 performed better than placebo at the 3 month time point. Company learned from 1301 and is incorporating more doses and spread out dosing through proliferation phase in the second hypertrophic scar study 1402.
Keloid trial was check out by panel of dermatologists who determined RXi-109 performed better than placebo at the 3 month time point. Panel unanimously recommended that Rxi being another keloid trial (like the 2nd hypertrophic scar trial) to add more doses and higher doses to improve efficacy even more.
Samcyprone will start soon with phase 2b trials by the end of 2015 with collaborations targeting warts, alopecia aerata, and metastatic melanoma (skin cancer)
Retinal scarring IND will be filed in mid 2015 (a few weeks months from now) and will first target the scarring of macular degeneration. Company will then begin phase 1 trial
Company should announce soon those new targets they announced collagenese/Tyrosinsae.
Did I miss anything? The company is on track. All is in order, the only short term problem is cash and many are wondering why the company hasn't diluted by now? Maybe they have a deal lined up who knows? All I know is that I like what the CEO has done thus far and I trust him to build value for the future of Rxi Pharmaceuticals.
FBR Capital rates RXII a "Hold" rating with an $8 price target! Seems all is good here, time to load up before you get left out.
http://www.markets.co/rxi-pharmaceuticals-corp-nasdaqrxii-a-buy-fbr-capital/7909/
Another Collaboration agreement using Rxi's sd-rxRNA platform. I keep telling people that the tech works its just for scarring the doses need to be adjusted is all.
Lysaker, 7 April 2015 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company, today announced that it is initiating a pre-clinical research collaboration with RXi Pharmaceuticals (NASDAQ: RXII), an American biotechnology company focused on discovering and developing innovative therapeutics, that address high-unmet medical needs primarily in the area of dermatology and ophthalmology. The partnership is governed by a pre-clinical research collaboration agreement.
Initially, the purpose of the pre-clinical research collaboration is to utilize the companies’ complementary scientific platforms to explore potential synergies.
In brief the pre-clinical research collaboration will evaluate technology compatibility based on in vitro and in vivo studies. The costs related to the research collaboration will be covered by each company separately. The companies will evaluate results achieved from this research collaboration and then explore the potential for a closer collaboration.
Both companies will retain exclusive ownership rights to existing registered intellectual property. However, any inventions arising from the collaboration will be jointly owned by the companies.
RXi Pharmaceuticals Provides Positive Update On Phase 2a Trials And Collaborations
http://www.talkmarkets.com/content/news/rxi-pharmaceuticals-provides-positive-update-on-phase-2a-trials-and-collaborations?post=61422
Look I normally don't like to chime in but I think everyone here is too passive and thinking blue skies ahead. I see this as a scam not because of the many reasons others have listed but because of the science.
You look at any other biotechnology company and even with a NCE -- New Chemical entity-- at most it takes 5 to 6 months to file an IND with the FDA. This company has been promising an IND for over more than a year and a half right now. What's the hold up?? That's why these companies trade on the pink sheets because they don't have to keep up to date filings if they don't want to. Understand that these penny stocks typically are a lot riskier than biotech stocks on the NASDAQ and a lot riskier than everything else because of the lack of transparency. Koos could keep strining people along for another 2 years claiming an IND is coming.
This reminds me of MCET where nothing happens just smokes and mirrors.
This news is huge patent for wet age-related macular degeneration and diabetic retinopathy.
ARLBOROUGH, Mass., Feb. 3, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO) for the delivery of double stranded siRNAs (21 to 23 nucleotides in length) across the blood-retina barrier (e.g. topical or systemic delivery) for the treatment of wet age-related macular degeneration or diabetic retinopathy. The patent, part of RXi's acquired OPKO estate, is scheduled to expire in 2023.
"This patent, in combination with our issued sd-rxRNA® patents, expands the scope of our intellectual property position in the area of Ophthalmology," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Not only does this further contribute to the potential commercial and business development opportunities in the future, it is another step towards achieving our long term goals for the acquired OPKO patent estate. Moreover, it further demonstrates our firm commitment to the development of our core technology platform as the key builder of our corporate value".
http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-120200596.html
RXi Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
http://finance.yahoo.com/news/rxi-pharmaceuticals-present-17th-annual-120200446.html
This time The chief Scientific Officer is presenting so it's possible more clinical results.
How do you know they are gonna get FDA approval on IND? What if FDA stalls for more questions then back to the drawing board again and KOOS will still continue to make a Salary.
Good article out for Regulus Therapeutics http://www.talkmarkets.com/content/us-markets/regulus-therapeutics-continues-its-uptrend-after-positive-data-in-early-hepatitis-c-study?post=51615
Here is an article for NWBO that I wrote Enjoy the great read.
"Northwest Biotherapeutics: A Variety Of Possibilities With The Future Of Immunotherapy Treatments"
http://www.talkmarkets.com/content/stocks--equities/northwest-biotherapeutics-a-variety-of-possibilities-with-the-future-of-immunotherapy-treatments?post=51418
Now it will probably go up steadily, but I think a lot of good results will be coming up. 2015 is even better IMO because that's when a lot of early results will be seen for ophthalmology.
Here are some Catalysts to watch for in 2015:
1. More 3-month results from hypertrophic scars early 2015
2. keloid 1-month and 3-month results early 2015
3. Early results from other hypertrophic scar study
4. IND for RXI-109 in PVR and other eye diseases
5. pre-clinical results from mac degeneration, retinoblastoma, etc.
6. Finally last but not least the adding of an additional phase 2 product to pipeline. I'm still not clear what this means but it is coming for 2015 and I don't see how the company would have money to acquire phase 2 ready product. I think it is some type of partnership/collaboration IMO.
RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109
MARLBOROUGH, Mass., Oct. 7, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that a review of the first two enrolled patients' clinical photographs in the first Phase 2a clinical trial (RXI-109-1301), indicate that treatment with the Company's lead clinical candidate, RXI-109, may be effective in suppressing recurrence of hypertrophic scars at the 3-month time point. Patients will continue to be monitored through 9 months to evaluate if this outcome persists over time.
On September 10th of this year, the Company announced that based on early 1-month observations, the dosing regimen in these trials can be fine-tuned, allowing the Company to more rapidly move forward with treatment optimization for the prevention of scarring after surgery. Today's presentation will provide 3-month photographs from the first two patients enrolled in study RXI-109-1301 that indicate treatment with RXI-109 shows a clinical benefit. The safety information in this ongoing study to date, continues to confirm that RXI-109 is well tolerated with no overt systemic side effects. Local effects are mild and similar to those seen in the Company's prior Phase 1 clinical trials (erythema, occasional, transient burning or stinging sensation). Complete 3-month results from this trial are expected to be available in Q1 2015.
"We are encouraged by the preliminary results in this trial," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. "To date, our Phase 2a studies are providing us with exactly the information for which such studies are intended, early information on dosing requirements and observation of a clinical effect of the drug. Having this information in hand now should save money and time going forward in our clinical development as we will incorporate these learnings into future clinical protocols."
Yep tell that to all the traders lol. Anyways yes long term this is golden. The 1-month results were great. I mean what were people expecting after one month? The hypertrophic scar hasn't even had time to grow back in one month. It takes 3 to 6 months to grow back!
Probably IND filing for PVR in 2 months possibly as next catalyst
My Seeking Alpha article interview with the CEO of RXII (Rxi pharmaceuticals) enjoy guys!
http://seekingalpha.com/article/2514825-rxi-pharmaceuticals-interview-with-ceo-post-phase-2a-interim-data
undiscovered gem IMO> you should have been here before the recent run up volume used to average only 40k to 60k shares a day. Now it averages 800k a day. In due time it will take off, I am long term so I am patient.
Next presentation though is important. It's a partnering conference. Each biotech sits down with 10 pharma companies in attempt to make a deal.......
1 year and 6 months thus far and no IND for Hemax. And you believe its certain ? yah okay lol!
Oh wait ENTB will hit 000's first, then BMSN thereafter. Koos will keep stringing all 3 companies along so he can keep getting paid thousands of dollars until retirement.
Okay even if you take away phase 3, you have to run phase 1, then find partner after phase 2. Bottom line this has been stuck in IND for way too long. other biotechs like Rexahn and other companies don't take this long even with new chemical entities.